CA2328331A1 - Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph - Google Patents

Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph Download PDF

Info

Publication number: CA2328331A1
Authority: CA; Canada
Prior art keywords: carnitine; nadh; composition; alkanoyl; pharmacologically acceptable
Prior art date: 1998-04-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002328331A

Other languages

English (en)

French (fr)

Inventor

Claudio Cavazza

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sigma Tau HealthScience SpA

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-17

Filing date

1999-04-14

Publication date

1999-10-28

1999-04-14 Application filed by Individual filed Critical Individual

1999-10-28 Publication of CA2328331A1 publication Critical patent/CA2328331A1/en

Status Abandoned legal-status Critical Current

Links

PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 62
239000000203 mixture Substances 0.000 title claims abstract description 24
-1 alkanoyl l-carnitine Chemical compound 0.000 title claims description 12
229960001518 levocarnitine Drugs 0.000 title 2
ACFIXJIJDZMPPO-NCHANQSKSA-N nadph Chemical compound C1=CCC(C(=O)N)=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2[C@@H]([C@H](OP(O)(O)=O)[C@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NCHANQSKSA-N 0.000 title 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 86
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract description 71
239000003814 drug Substances 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 13
235000015872 dietary supplement Nutrition 0.000 claims abstract description 6
239000002253 acid Substances 0.000 claims description 18
ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical group C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 claims description 15
125000002252 acyl group Chemical group 0.000 claims description 11
239000002243 precursor Substances 0.000 claims description 8
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 8
RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 7
239000005515 coenzyme Substances 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims description 5
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 4
229910019142 PO4 Inorganic materials 0.000 claims description 4
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
229940009098 aspartate Drugs 0.000 claims description 4
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
239000010452 phosphate Substances 0.000 claims description 4
229910021653 sulphate ion Inorganic materials 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 3
239000002552 dosage form Substances 0.000 claims description 3
IGQBPDJNUXPEMT-SNVBAGLBSA-N isovaleryl-L-carnitine Chemical compound CC(C)CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IGQBPDJNUXPEMT-SNVBAGLBSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 2
QWYFHHGCZUCMBN-SECBINFHSA-N O-butanoyl-L-carnitine Chemical compound CCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C QWYFHHGCZUCMBN-SECBINFHSA-N 0.000 claims description 2
VSNFQQXVMPSASB-SNVBAGLBSA-N O-valeroyl-L-carnitine Chemical compound CCCCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C VSNFQQXVMPSASB-SNVBAGLBSA-N 0.000 claims description 2
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
239000003963 antioxidant agent Substances 0.000 claims description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 2
229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
239000011707 mineral Substances 0.000 claims description 2
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 2
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 2
229940095064 tartrate Drugs 0.000 claims description 2
229940066528 trichloroacetate Drugs 0.000 claims description 2
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 2
239000011782 vitamin Substances 0.000 claims description 2
229930003231 vitamin Natural products 0.000 claims description 2
229940088594 vitamin Drugs 0.000 claims description 2
235000013343 vitamin Nutrition 0.000 claims description 2
BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 claims 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 1
229960000643 adenine Drugs 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 abstract description 8
206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract description 7
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract description 7
125000001589 carboacyl group Chemical group 0.000 abstract description 3
XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 abstract 1
229960004203 carnitine Drugs 0.000 description 24
238000012360 testing method Methods 0.000 description 18
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 15
230000000694 effects Effects 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 13
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 10
241001465754 Metazoa Species 0.000 description 10
229940079593 drug Drugs 0.000 description 10
230000009467 reduction Effects 0.000 description 10
206010021143 Hypoxia Diseases 0.000 description 9
IDAICLIJTRXNER-UHFFFAOYSA-N 5,6,7,8-tetrahydropteridine Chemical compound C1=NC=C2NCCNC2=N1 IDAICLIJTRXNER-UHFFFAOYSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
229960003638 dopamine Drugs 0.000 description 8
230000007954 hypoxia Effects 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
230000004899 motility Effects 0.000 description 7
210000003205 muscle Anatomy 0.000 description 7
241000699670 Mus sp. Species 0.000 description 6
208000027089 Parkinsonian disease Diseases 0.000 description 6
206010034010 Parkinsonism Diseases 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
208000024891 symptom Diseases 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
201000010099 disease Diseases 0.000 description 5
238000000034 method Methods 0.000 description 5
230000001575 pathological effect Effects 0.000 description 5
210000002027 skeletal muscle Anatomy 0.000 description 5
239000000758 substrate Substances 0.000 description 5
ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
230000006870 function Effects 0.000 description 4
230000001965 increasing effect Effects 0.000 description 4
229960004502 levodopa Drugs 0.000 description 4
230000002503 metabolic effect Effects 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
230000002438 mitochondrial effect Effects 0.000 description 4
230000003387 muscular Effects 0.000 description 4
210000003540 papillary muscle Anatomy 0.000 description 4
230000037081 physical activity Effects 0.000 description 4
230000003449 preventive effect Effects 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
206010058892 Carnitine deficiency Diseases 0.000 description 3
102100022317 Dihydropteridine reductase Human genes 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
101710088929 Voltage-dependent L-type calcium channel subunit alpha-1S Proteins 0.000 description 3
230000009471 action Effects 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
230000002045 lasting effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
208000030507 AIDS Diseases 0.000 description 2
208000024827 Alzheimer disease Diseases 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
108010066477 Carnitine O-acetyltransferase Proteins 0.000 description 2
102100036357 Carnitine O-acetyltransferase Human genes 0.000 description 2
108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
102000018832 Cytochromes Human genes 0.000 description 2
108010052832 Cytochromes Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010019233 Headaches Diseases 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
208000031226 Hyperlipidaemia Diseases 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
208000007873 MPTP Poisoning Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
CNIUEVQJABPUIJ-QMMMGPOBSA-N N-hydroxytyrosine Chemical compound ON[C@H](C(O)=O)CC1=CC=C(O)C=C1 CNIUEVQJABPUIJ-QMMMGPOBSA-N 0.000 description 2
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 2
206010029260 Neuroblastoma Diseases 0.000 description 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 2
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
230000008499 blood brain barrier function Effects 0.000 description 2
210000001218 blood-brain barrier Anatomy 0.000 description 2
229960004205 carbidopa Drugs 0.000 description 2
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 2
108010076625 carnitine octanoyltransferase Proteins 0.000 description 2
235000017471 coenzyme Q10 Nutrition 0.000 description 2
229940110767 coenzyme Q10 Drugs 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
206010016256 fatigue Diseases 0.000 description 2
231100000869 headache Toxicity 0.000 description 2
230000006872 improvement Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
150000004668 long chain fatty acids Chemical class 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
208000029372 muscular lipidosis Diseases 0.000 description 2
229950006238 nadide Drugs 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000003647 oxidation Effects 0.000 description 2
238000007254 oxidation reaction Methods 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
230000035806 respiratory chain Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000820 toxicity test Toxicity 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
WGVIDFOIIXIJGV-UHFFFAOYSA-N 1-butan-2-yloxy-4-phenylpiperidine Chemical compound CC(CC)ON1CCC(CC1)C1=CC=CC=C1 WGVIDFOIIXIJGV-UHFFFAOYSA-N 0.000 description 1
PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 1
USUUKNCFNKZGEY-UHFFFAOYSA-N 1-tert-butyl-4,4-diphenylpiperidin-1-ium;chloride Chemical compound Cl.C1CN(C(C)(C)C)CCC1(C=1C=CC=CC=1)C1=CC=CC=C1 USUUKNCFNKZGEY-UHFFFAOYSA-N 0.000 description 1
WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
230000002407 ATP formation Effects 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
206010002660 Anoxia Diseases 0.000 description 1
241000976983 Anoxia Species 0.000 description 1
102100038238 Aromatic-L-amino-acid decarboxylase Human genes 0.000 description 1
208000006820 Arthralgia Diseases 0.000 description 1
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
206010010305 Confusional state Diseases 0.000 description 1
208000032131 Diabetic Neuropathies Diseases 0.000 description 1
208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
206010022998 Irritability Diseases 0.000 description 1
102000012011 Isocitrate Dehydrogenase Human genes 0.000 description 1
108010075869 Isocitrate Dehydrogenase Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
208000001089 Multiple system atrophy Diseases 0.000 description 1
208000007101 Muscle Cramp Diseases 0.000 description 1
206010049565 Muscle fatigue Diseases 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
201000009623 Myopathy Diseases 0.000 description 1
102000006746 NADH Dehydrogenase Human genes 0.000 description 1
108010086428 NADH Dehydrogenase Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
206010031127 Orthostatic hypotension Diseases 0.000 description 1
241000283977 Oryctolagus Species 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
229920005372 Plexiglas® Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108010035075 Tyrosine decarboxylase Proteins 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229940124326 anaesthetic agent Drugs 0.000 description 1
230000003444 anaesthetic effect Effects 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000007953 anoxia Effects 0.000 description 1
230000000879 anti-atherosclerotic effect Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
ZCHMSSOGPAFJTM-UHFFFAOYSA-N butanedioic acid 1-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CCC(O)=O.OC(C(CC(O)=O)C(O)=O)C(O)=O ZCHMSSOGPAFJTM-UHFFFAOYSA-N 0.000 description 1
FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000000385 dialysis solution Substances 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
210000005064 dopaminergic neuron Anatomy 0.000 description 1
230000000142 dyskinetic effect Effects 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000009088 enzymatic function Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
206010020765 hypersomnia Diseases 0.000 description 1
230000003483 hypokinetic effect Effects 0.000 description 1
239000002117 illicit drug Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000001617 migratory effect Effects 0.000 description 1
210000001700 mitochondrial membrane Anatomy 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
230000002107 myocardial effect Effects 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
101150006061 neur gene Proteins 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
230000007823 neuropathy Effects 0.000 description 1
230000003557 neuropsychological effect Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
229960003966 nicotinamide Drugs 0.000 description 1
235000005152 nicotinamide Nutrition 0.000 description 1
239000011570 nicotinamide Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000002859 orphan drug Substances 0.000 description 1
229940000673 orphan drug Drugs 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
230000010627 oxidative phosphorylation Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
208000033808 peripheral neuropathy Diseases 0.000 description 1
229960000482 pethidine Drugs 0.000 description 1
229950000688 phenothiazine Drugs 0.000 description 1
239000004926 polymethyl methacrylate Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
235000008160 pyridoxine Nutrition 0.000 description 1
239000011677 pyridoxine Substances 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
229910052711 selenium Inorganic materials 0.000 description 1
239000011669 selenium Substances 0.000 description 1
230000035807 sensation Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
210000003699 striated muscle Anatomy 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000009044 synergistic interaction Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
230000003867 tiredness Effects 0.000 description 1
208000016255 tiredness Diseases 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
238000009602 toxicology test Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
201000002282 venous insufficiency Diseases 0.000 description 1
229940011671 vitamin b6 Drugs 0.000 description 1
230000003245 working effect Effects 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002328331A 1998-04-17 1999-04-14 Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph Abandoned CA2328331A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
ITRM98A000238		1998-04-17
IT98RM000238A IT1299161B1 (it)	1998-04-17	1998-04-17	Composizione comprendente l-carnitina o un'alcanoil l-carnitina e nadh e/o nadph
PCT/IT1999/000088 WO1999053921A1 (en)	1998-04-17	1999-04-14	Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph

Publications (1)

Publication Number	Publication Date
CA2328331A1 true CA2328331A1 (en)	1999-10-28

Family

ID=11405812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002328331A Abandoned CA2328331A1 (en)	1998-04-17	1999-04-14	Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph

Country Status (17)

Country	Link
EP (1)	EP1071424A1 (no)
JP (1)	JP2002512191A (no)
KR (1)	KR20010042765A (no)
CN (1)	CN1299283A (no)
AU (1)	AU750645B2 (no)
BR (1)	BR9909712A (no)
CA (1)	CA2328331A1 (no)
EE (1)	EE200000601A (no)
HU (1)	HUP0101914A3 (no)
IL (1)	IL139014A0 (no)
IS (1)	IS5663A (no)
IT (1)	IT1299161B1 (no)
NO (1)	NO20005128L (no)
PL (1)	PL343482A1 (no)
SK (1)	SK15442000A3 (no)
TR (1)	TR200002894T2 (no)
WO (1)	WO1999053921A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8252309B2 (en)	2000-04-04	2012-08-28	Sigma-Tau Industrie Farmaceutiche Riunite Spa	Dietary supplement energy-providing to skeletal muscles
DE10326822A1 (de) *	2003-06-11	2005-01-05	Herzpharma Vita-Check Diagnosegeräte GmbH	Mittel zur Nahrungsergänzung, dieses Mittel enthaltende pharmazeutische Präparate und Verwendungen des Mittels
BRPI0721698A2 (pt) *	2007-05-11	2013-01-22	Sigma Tau Ind Famaceutiche Riunite S P A	gel étil para a liberaÇço de ingredientes ativos cosmÉticos
AU2010286348A1 (en) *	2009-08-31	2012-03-22	University Of South Australia	Methods for diagnosis and treatment of chronic fatigue syndrome
CN104306390A (zh) *	2014-10-23	2015-01-28	苏州人本药业有限公司	还原型辅酶ⅱ的用途
CN104840479A (zh) *	2015-02-17	2015-08-19	苏州人本药业有限公司	Nadph在制备治疗心脏疾病药物中的应用
CN109496154B (zh) *	2017-12-22	2021-07-06	邦泰生物工程(深圳)有限公司	一种nadh复方组合物及其制剂和应用
JP7130844B2 (ja)	2018-04-20	2022-09-05	パコトレードアクチェンゲゼルシャフト	ブロック状で提供される冷凍食品を細断するための装置
CN109105702A (zh) *	2018-08-30	2019-01-01	泓博元生命科技（深圳）有限公司	一种含有nadh的组合物、应用及能量补充剂的制备方法
CN109170907A (zh) *	2018-08-30	2019-01-11	泓博元生命科技（深圳）有限公司	一种含有nmn的组合物、应用及运动饮料的制备方法
CA3115743A1 (en) *	2018-10-10	2020-04-16	So Ngor Sally LEUNG	Health-care product composition for enriching asthenic disease, preparation method therefor and use thereof
CN117958433A (zh) *	2024-03-22	2024-05-03	四川新渔新美健康科技有限公司	不含咖啡因的抗疲劳功能组合物、饮料

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1054698A (no) *	1964-12-04
US5292538A (en) *	1992-07-22	1994-03-08	Metagenics, Inc.	Improved sustained energy and anabolic composition and method of making
DE4335454A1 (de) *	1993-10-19	1995-04-20	Schleicher Peter	Geriatrikum
JPH09110708A (ja) *	1995-08-11	1997-04-28	Taisho Pharmaceut Co Ltd	滋養強壮用生薬配合製剤
JPH0959161A (ja) *	1995-08-23	1997-03-04	Taisho Pharmaceut Co Ltd	疲労改善用組成物
IT1277953B1 (it) *	1995-12-21	1997-11-12	Sigma Tau Ind Farmaceuti	Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per
IT1283951B1 (it) *	1996-03-15	1998-05-07	Mendes Srl	Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
US5712259A (en) *	1996-04-22	1998-01-27	Birkmayer Pharmaceuticals	NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US6077828A (en) *	1996-04-25	2000-06-20	Abbott Laboratories	Method for the prevention and treatment of cachexia and anorexia
JPH10175856A (ja) *	1996-10-14	1998-06-30	Taisho Pharmaceut Co Ltd	疲労改善剤

1998
- 1998-04-17 IT IT98RM000238A patent/IT1299161B1/it active IP Right Grant
1999
- 1999-04-14 CN CN99805644A patent/CN1299283A/zh active Pending
- 1999-04-14 SK SK1544-2000A patent/SK15442000A3/sk unknown
- 1999-04-14 EP EP99916039A patent/EP1071424A1/en not_active Withdrawn
- 1999-04-14 IL IL13901499A patent/IL139014A0/xx unknown
- 1999-04-14 BR BR9909712-5A patent/BR9909712A/pt not_active IP Right Cessation
- 1999-04-14 TR TR2000/02894T patent/TR200002894T2/xx unknown
- 1999-04-14 AU AU34428/99A patent/AU750645B2/en not_active Ceased
- 1999-04-14 WO PCT/IT1999/000088 patent/WO1999053921A1/en not_active Ceased
- 1999-04-14 PL PL99343482A patent/PL343482A1/xx not_active Application Discontinuation
- 1999-04-14 CA CA002328331A patent/CA2328331A1/en not_active Abandoned
- 1999-04-14 KR KR1020007011499A patent/KR20010042765A/ko not_active Withdrawn
- 1999-04-14 HU HU0101914A patent/HUP0101914A3/hu unknown
- 1999-04-14 EE EEP200000601A patent/EE200000601A/xx unknown
- 1999-04-14 JP JP2000544325A patent/JP2002512191A/ja active Pending
2000
- 2000-10-12 NO NO20005128A patent/NO20005128L/no not_active Application Discontinuation
- 2000-10-13 IS IS5663A patent/IS5663A/is unknown

Also Published As

Publication number	Publication date
EP1071424A1 (en)	2001-01-31
IL139014A0 (en)	2001-11-25
TR200002894T2 (tr)	2001-01-22
EE200000601A (et)	2002-04-15
HUP0101914A3 (en)	2002-12-28
NO20005128D0 (no)	2000-10-12
CN1299283A (zh)	2001-06-13
ITRM980238A1 (it)	1999-10-17
JP2002512191A (ja)	2002-04-23
ITRM980238A0 (it)	1998-04-17
IS5663A (is)	2000-10-13
IT1299161B1 (it)	2000-02-29
NO20005128L (no)	2000-12-18
WO1999053921A1 (en)	1999-10-28
AU750645B2 (en)	2002-07-25
PL343482A1 (en)	2001-08-27
BR9909712A (pt)	2000-12-26
KR20010042765A (ko)	2001-05-25
AU3442899A (en)	1999-11-08
SK15442000A3 (sk)	2001-06-11
HUP0101914A2 (hu)	2002-03-28

Legal Events

Date	Code	Title	Description
2004-04-14	FZDE	Discontinued

Publication	Publication Date	Title
EP0973415B1 (en)	2001-07-04	Nutritional supplement
Abraham et al.	1992	Management of fibromyalgia: rationale for the use of magnesium and malic acid
US12350243B2 (en)	2025-07-08	Compositions and compounds containing beta-hydroxybutyrate and one or more amino acids
US8747906B2 (en)	2014-06-10	Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose
HUE032486T2 (en)	2018-05-02	An improved method for administering beta-hydroxy-beta-methylbutyrate (HMB)
AU4575299A (en)	2000-01-05	Compositions for increasing energy (in vivo)
AU750645B2 (en)	2002-07-25	Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH
US5656608A (en)	1997-08-12	Amino acid compositions and methods of treatment using same
US5712259A (en)	1998-01-27	NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
CZ20014077A3 (cs)	2002-03-13	Doplňková výľiva dodávající energii kosternímu svalstvu a chránící kardiovaskulární systém
MXPA00009983A (en)	2001-11-21	Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
ES2269355T3 (es)	2007-04-01	Composicion para la prevencion y/o tratamiento de enfermedades vasculares, constituida por l-carnitina de propionil y coencima q10.
CZ20003831A3 (cs)	2001-04-11	Přípravek obsahující L-karnitin nebo alkanoyl Lkarnitinu a NADH a/nebo NADPH
US12599579B2 (en)	2026-04-14	Compositions and compounds containing ketone bodies and/or ketone body precursors and one or more amino acids
HK1036589A (en)	2002-01-11	Composition comprising l-carnitine or an alkanoyl l-carnitine and nadh and/or nadph
KR20240152875A (ko)	2024-10-22	L-트립토판, l-5-하이드록시트립토판 및 말초 분해 억제제를 포함하는 약학 조성물 및 약제
MXPA99008999A (en)	2000-02-02	Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals
CZ347999A3 (cs)	2000-02-16	Doplňková výživa pro snazší adaptaci kosterního svalstva vyčerpaného zatěžujícími výkony a paralyzování únavy asthenických jedinců
HK1026124B (en)	2002-04-19	Nutritional supplement